Paulson & Co’s Travere Therapeutics TVTX Stock Holding History

Paulson & Co’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-55,000	Closed	-$1.04M	–	113
2016 Q4	$1.04M	Buy	+55,000	New	+$1.12M	0.01%	91

Other funds holding TVTX

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Paulson & Co's TVTX Position: Q1 2017 in Review

Paulson & Co sold out of Travere Therapeutics (TVTX) in Q1 2017, closing a stake of 55,000 shares — an estimated $1.04M sold.

Paulson & Co first reported a position in TVTX in Q4 2016 and held it in 1 quarter. The position peaked at $1.04M in Q4 2016. 114 funds tracked by Wall St. Rank hold TVTX as of Q1 2017.

Paulson & Co reported no remaining Travere Therapeutics position as of Q1 2017 after selling out during the quarter.
Paulson & Co sold 55,000 Travere Therapeutics shares in Q1 2017, an estimated $1.04M.
Paulson & Co first reported a position in Travere Therapeutics in Q4 2016 and held it in 1 quarter.
Paulson & Co's Travere Therapeutics position peaked at $1.04M in Q4 2016.
114 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2017.

Based on Paulson & Co's 13F filing for Q1 2017, filed 15 May 2017.